胸腺素辅助治疗耐多药肺结核34例

目的：探讨耐多药结核病的治疗方法。方法： 将68例耐多药肺结核患者随机分为治疗组和对照组各34例。两组患者的化疗方案均为3AMIDZOE/6DEO，强化期3个月，继续期在痰菌阴转6个月后停药。治疗组在强化期加用胸腺素100 mg加入0.9%氯化钠注射液100 mL，静脉滴注，qd，4周后，改为每周3次，连用4周。结果： 治疗组6，9个月痰菌阴转率均为76.5%，明显高于对照组(50.0%，47.1%)，二者差异有显著性(P＜0.05)；治疗组空洞闭合率78.2%，明显高于对照组(50.0%)(P＜0.05)。结论： 胸腺素辅助治疗耐多药肺结核疗效显著。

Clinical Controlled Study on Efficacy of Thymosin in Treatment of Multidrug Resistant Pulmonary Tuberculosis

Objective:To explore the effect of thymosin in the treatment of multidrug resistance (MTB) pulmonary tuberculosis. Methods:Sixty-eight suitable patients were randomized into two groups: the treatment and the control with 34 cases in each group. Both groups received the same chemotherapy scenario: 3AMIDZOE/6DEO, strengthening treatment for 3 months, succeeding treatment for 6 months after the negative result of sputum examination for tubercle bacillus. The treatment group also received thymosin 100 mg dissolved in 250 mL sodium chloride injection by intravenous infusion daily in succeeding period. Results: Negative conversions in treatment group for 6 months, 9 months were both 76.5%, significantly higher than 50.0%, 47.1% in control group (P<0.05). The rate of closed cavity was 78.2% in the former also significantly higher than 50.0% (P<0.05) in the latter. Conclusions:Thymosin in treatment MDR pulmonary tuberculosis is obvious effect.